Tesamorelin has a long name and it also has a long chain of 44 amino acids to match. It is a peptide that tells your pituitary gland to release more of its own growth hormone. It is best known for its effect on deep belly fat.
Tesamorelin is the active ingredient in an FDA approved prescription medicine for a specific group of patients. Many claims online go well beyond that approval. We will keep every claim in this guide tied to what research actually shows.
What Is Tesamorelin?
Tesamorelin is a synthetic version of growth hormone releasing hormone. Scientists call this hormone GHRH. Your brain makes GHRH naturally and it tells the pituitary gland to release growth hormone.
Tesamorelin copies the whole GHRH chain which has 44 amino acids. A small chemical group is added to the front end of the chain. This helps protect it from an enzyme called DPP IV that normally breaks GHRH down very quickly.
The prescription medicine made with tesamorelin is called Egrifta. The FDA approved it in 2010.
How Does Tesamorelin Work?
Here is the process in simple steps.
- Tesamorelin signals the pituitary gland to release growth hormone.
- Growth hormone travels through the body and raises a second signal called IGF 1.
- Growth hormone also helps the body break down stored fat for energy.
Tesamorelin does not supply growth hormone from outside. It asks your own pituitary to make it. This is the same basic idea behind peptides such as CJC 1295 and sermorelin.
How Is Tesamorelin Different From CJC 1295 and Sermorelin?
CJC 1295 and sermorelin are shorter pieces of the GHRH chain. Tesamorelin is the full length chain with a protective change. Think of the shorter pieces as sticky notes that fall off the wall quickly. Tesamorelin is more like a note pinned in place with a tack.
One source notes that no head to head trial has compared tesamorelin with sermorelin. So we cannot say that one works better than the other.
Why Is Tesamorelin Linked With Visceral Fat?
There are two main kinds of body fat. Fat under the skin is easy to see and pinch. Visceral fat sits deep in the belly around the organs. It is linked with a higher risk of health problems.
Growth hormone helps the body use stored fat. Researchers believe visceral fat may respond strongly to this signal. This is one reason tesamorelin was studied for deep belly fat.
Is Tesamorelin FDA Approved?
Yes for one specific use. Egrifta is approved to reduce extra belly fat in adults with HIV who have a condition called lipodystrophy. It is given as a daily injection under the skin. It is not approved for general weight loss.
In the large trials in adults with HIV deep belly fat dropped by about 15 percent with tesamorelin. In one trial of 412 people visceral fat fell by 15.2 percent while it rose by 5.0 percent with placebo. A combined look at 806 people found a similar result after 26 weeks.
There is an important catch. When people stopped treatment the visceral fat tended to move back toward where it started. Continued use appears to be needed to keep the effect.
Does Tesamorelin Help Fatty Liver?
This is a promising area. In a randomised and double blind trial 61 adults with HIV and fatty liver received tesamorelin or placebo for 12 months. Liver fat fell by about 37 percent compared with placebo. About 35 percent of the tesamorelin group dropped below the fatty liver cut off compared with 4 percent of the placebo group.
Please note who was studied. These were adults with HIV and the trial was small. The authors said that tesamorelin might be helpful and that more work is needed. Fatty liver is not an approved use.
Other Claims You May Hear
Some online sources say tesamorelin turns white fat into brown fat or switches on special heat making proteins. We could not confirm these explanations in the sources we checked. Treat them as ideas and not as facts.
You may also hear that tesamorelin sharpens thinking. An early small study in older adults reported better executive function. This needs much more research before anyone can make a claim.
Tesamorelin Evidence at a Glance
| Area | What research found | Strength of evidence |
|---|---|---|
| Visceral fat in adults with HIV | About 15 percent less visceral fat in large trials | Strong and the basis for FDA approval |
| Keeping the fat off | Visceral fat tends to return after stopping | Reported in extension data |
| Fatty liver in adults with HIV | About 37 percent less liver fat in a trial of 61 people | Promising but small |
| Fat loss in people without HIV | Studied but not approved | Limited |
| Thinking and memory | Early small study only | Early |
| Brown fat and heat claims | Not confirmed in the sources we checked | Not established |
Tesamorelin Side Effects and Safety
Because tesamorelin acts on the growth hormone pathway it can cause effects linked to growth hormone. Here is what trials and the prescription information report.
- Injection site reactions are the most common effect.
- Joint pain and muscle pain and pain in the arms or legs.
- Swelling from fluid retention and tingling or numbness.
- Higher blood sugar. In one trial more people on tesamorelin reached a blood sugar marker of 6.5 percent or higher than people on placebo.
- Higher IGF 1 which doctors monitor during treatment.
- Allergic reactions. About 4 percent of trial patients had a hypersensitivity reaction.
Growth hormone can also encourage tissue growth. Because of this there is a concern about tumours. The prescription information lists active cancer as a reason not to use tesamorelin. Anyone with a history of cancer should speak with a doctor.
Who Should Avoid Tesamorelin?
- People who are pregnant
- People with active cancer
- People with a known allergy to tesamorelin
- People with pituitary problems such as a pituitary tumour or past head radiation
This blog is for education only and is not medical advice. Always speak with a qualified doctor about your own health.
Research Tesamorelin vs Egrifta
Egrifta is a prescription medicine made and checked under strict rules and approved for one use. Tesamorelin sold as a research peptide is a different product for laboratory use. It is not a substitute for the medicine. Uses and amounts promoted online for fat loss are not backed by the approval.
Why Quality and Sourcing Matter
Because the evidence outside the approved use is still limited the quality of the material matters even more. A vial with no clear label is like a parcel with no address and nobody should have to guess where it came from. Peptides from unclear sources can be mislabelled or contaminated and that makes any result hard to trust.
At Genesis Peptides we supply research peptides in the UK. Our products are for laboratory research use only and not for human consumption. We believe every researcher deserves clear information and honest labelling.
Looking for Research Peptides in the UK?
Genesis Peptides is here to help UK researchers find the right peptides with clear and honest information. Our products are for research use only. Have a question about tesamorelin or any other peptide on our website? Call us or message us on WhatsApp at +44 7343 047659 and our team will be happy to help.
Conclusion
So what is tesamorelin and how does it work? It is a full length GHRH analog that tells the pituitary to release growth hormone. It has FDA approval for extra belly fat in adults with HIV and the visceral fat results are solid. Fatty liver results are promising but small and many online claims go beyond the evidence.
The honest summary is that tesamorelin is a well studied peptide for one specific use and a research topic for everything else. Keep your expectations realistic and always choose a source you can trust. Genesis Peptides is here to support your research with clear information and honest labelling.
Frequently asked questions
What is tesamorelin?
Tesamorelin is a synthetic version of growth hormone releasing hormone with 44 amino acids. It signals the pituitary gland to release growth hormone. A prescription medicine called Egrifta contains it and the FDA approved it in 2010 for extra belly fat in adults with HIV lipodystrophy.
How does tesamorelin work?
Tesamorelin tells the pituitary gland to release its own growth hormone. Growth hormone then raises IGF 1 and helps the body break down stored fat. A small change to the chain helps it resist an enzyme called DPP IV so it lasts longer than shorter fragments.
Does tesamorelin reduce belly fat?
In adults with HIV and lipodystrophy yes. Large trials showed about 15 percent less visceral fat. The fat tended to return after stopping. It is not approved for general weight loss and evidence for people without HIV is limited.
Is tesamorelin FDA approved?
Yes but only for one use. The FDA approved Egrifta to reduce extra belly fat in adults with HIV lipodystrophy. It is not approved for general weight loss or fatty liver or any other use. Research tesamorelin is a different product.
Does tesamorelin help fatty liver?
It may. In a trial of 61 adults with HIV and fatty liver liver fat fell by about 37 percent over 12 months compared with placebo. The trial was small and only included people with HIV. More research is needed.
What are the side effects of tesamorelin?
Common effects include injection site reactions and joint or muscle pain and swelling and tingling. Blood sugar and IGF 1 can rise. Allergic reactions can happen. It is not for people who are pregnant or have active cancer. Speak with a doctor before any use.
What is the difference between tesamorelin and CJC 1295?
Both signal the pituitary to release growth hormone. CJC 1295 is a shorter piece of the GHRH chain. Tesamorelin is the full 44 amino acid chain with a protective change. Only tesamorelin has FDA approval for a medicine.